Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-210 versus intravesical chemotherapy in FGFR-altered high-risk non-muscle-invasive bladder cancer after BCG
ISRCTN16925539Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of erdafitinib, mitomycin c and gemcitabine in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Disease-free survival. Started Sep 2025; status: recruiting.
02
Drugs
erdafitinibmitomycin cgemcitabine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ISRCTN16925539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16925539.